Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC5 | O15392 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.30 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694088 | 0.84 | KCNH2 (0.39) | BIRC5SMN1; SMN2KDM4E | |
| SCHEMBL5800901 | 0.81 | KIF11 (0.34) | BIRC5L3MBTL1NOTUM | |
| SCHEMBL405614 | 0.74 | HTT (0.39) | HTTDDB1CRBNSMN1; SMN2ATM | |
| SCHEMBL30763485 | 0.71 | DDB1 (0.48) | BIRC5HTTDDB1CRBNSMN1; SMN2 | |
| SCHEMBL6466793 | 0.70 | ATM (0.34) | SMN1; SMN2ATMKDM4EL3MBTL1 | |
| SCHEMBL10971445 | 0.69 | — | — | |
| SCHEMBL1450364 | 0.69 | NQO2 (0.47) | KDM4E | |
| SCHEMBL6696299 | 0.69 | HTR6 (0.45) | SMN1; SMN2KDM4EL3MBTL1NOTUM | |
| SCHEMBL8802083 | 0.69 | CYP19A1 (0.33) | — | |
| SCHEMBL29475118 | 0.69 | BIRC5 (0.70) | BIRC5HTTL3MBTL1PLA2G4AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716160-B1 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-29 | — | — | EP | claimed |
| US-20100048513-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2010-02-25 | — | — | US | claimed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | claimed |
| US-20050176769-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | US | claimed |
| US-8546358-B2 | Method of treating asthma | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-01 | — | — | US | disclosed |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | HAWKINS MICHAEL J (US) | 2012-01-26 | — | — | US | disclosed |
| EP-1716160-B1 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-29 | — | — | EP | disclosed |
| US-20100048513-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2010-02-25 | — | — | US | disclosed |
| US-20100004221-A1 | THIAZEPINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2119719-A1 | THIAZEPINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| US-20050176769-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048513-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | BIRC5 753/4885HTT 4560/4885DDB1 2564/4885 |
| US-20100004221-A1 | THIAZEPINE DERIVATIVE | HSD11B1, HSD17B1, HSD3B1 | BIRC5 4285/4885HTT 3244/4885DDB1 2115/4885 |
| US-20050176769-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | BIRC5 753/4885HTT 4560/4885DDB1 2564/4885 |
| US-20090036409-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | BIRC5 753/4885HTT 4560/4885DDB1 2564/4885 |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | CMA1, SERPINB1, TPSAB1 | BIRC5 753/4885HTT 4560/4885DDB1 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.